Braidwell’s Denali Therapeutics DNLI Stock Holding History

Braidwell’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-296,324	Closed	-$5.69M	–	95
2026 Q1	$5.69M	Buy	+296,324	New	+$5.9M	0.19%	80
2024 Q1	–	Sell	-461,769	Closed	-$9.91M	–	73
2023 Q4	$9.91M	Buy	+461,769	New	+$9.15M	0.36%	60

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Braidwell's DNLI Position: Q2 2026 in Review

Braidwell sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 296,324 shares — an estimated $5.69M sold.

Braidwell first reported a position in DNLI in Q4 2023 and held it in 2 quarters. The position peaked at $9.91M in Q4 2023. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Braidwell reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Braidwell sold 296,324 Denali Therapeutics shares in Q2 2026, an estimated $5.69M.
Braidwell first reported a position in Denali Therapeutics in Q4 2023 and held it in 2 quarters.
Braidwell's Denali Therapeutics position peaked at $9.91M in Q4 2023.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.